Many studies have reported beneficial effects of pharmacological FGF21 administration, including improvements in hyperglycemia, insulin resistance, and dyslipidemia, reduced fat mass, and reversal of non-alcoholic steatohepatitis (NASH) [reviewed in (8, 9, and (10)]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.